Cardiol Therapeutics Inc.
CRDLAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 23, 2024 | Canaccord Genuity | Edward Nash | $8.00(+257%) | $2.24 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 23, 2026 |
| Canaccord Genuity | maintain | Buy | Aug 17, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 14, 2026 |
| Canaccord Genuity | maintain | Buy | Apr 6, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 24, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 7, 2024 |
| Canaccord Genuity | maintain | Buy | May 23, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2024 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.06| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.04 | $-0.09 | — | — |
| May 11, 2026 | $-0.07 | $-0.07 | — | — |
| Mar 30, 2026 | $-0.05 | $-0.09 | — | — |
| Nov 13, 2025 | $-0.09 | $-0.09 | — | — |
| Aug 14, 2025 | $-0.07 | $-0.11 | — | — |
| May 14, 2025 | $-0.07 | $-0.09 | — | — |
| Mar 31, 2025 | $-0.07 | $-0.08 | — | — |
| Nov 14, 2024 | $-0.13 | $-0.10 | — | — |
News
TORONTO, Nov. 3, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it has entered into a sales agreement (the "ATM Agreement") with Jefferies LLC (the "Sales Agent") for an at-the-market offering program (the "ATM Program"). The ATM Agreement will allow the Company to offer and sell up to US$75 million of c…
Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk.
Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028. TORONTO, Sept.
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada, together with a corresponding registration statement on Form F-10 …
TORONTO, Sept. 9, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C.
Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardiol Therapeutics NASDAQ: CRDL is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management describing the program as a key step toward a potential new drug application.